Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-Current Assets: 2020-2025

Historic Non-Current Assets for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $68.0 million.

  • Apellis Pharmaceuticals' Non-Current Assets rose 0.11% to $68.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.0 million, marking a year-over-year increase of 0.11%. This contributed to the annual value of $96.1 million for FY2024, which is 329.02% up from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Non-Current Assets is $68.0 million, which was up 3.45% from $65.8 million recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Non-Current Assets peaked at $96.1 million during Q4 2024, and registered a low of $20.5 million during Q1 2024.
  • Over the past 3 years, Apellis Pharmaceuticals' median Non-Current Assets value was $44.5 million (recorded in 2024), while the average stood at $48.5 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first crashed by 47.63% in 2023, then spiked by 329.02% in 2024.
  • Apellis Pharmaceuticals' Non-Current Assets (Quarterly) stood at $57.7 million in 2021, then declined by 29.50% to $40.7 million in 2022, then crashed by 44.96% to $22.4 million in 2023, then surged by 329.02% to $96.1 million in 2024, then rose by 0.11% to $68.0 million in 2025.
  • Its Non-Current Assets was $68.0 million in Q3 2025, compared to $65.8 million in Q2 2025 and $79.6 million in Q1 2025.